Single Dose Radiotherapy Services Market Snapshot (2023 to 2033)

The global single dose radiotherapy services market is expected to attain a valuation of US$ 7.88 billion in 2023 and is projected to reach US$ 16 billion by 2033, expanding at a CAGR of 7.3% during the forecast period.

Single Dose Radiotherapy is gaining popularity for the treatment of breast cancer and prostate cancer due to several advantages it offers. This advanced approach provides high precision, ensuring accurate targeting of cancer cells while maximizing patient comfort. It is additionally known for its cost-effectiveness and ability to produce favorable cosmetic outcomes.

The combination of its precision, patient comfort, cost-effectiveness, and improved cosmetic results has driven the growing adoption of single-dose radiotherapy services specifically for breast cancer and prostate cancer.

The global incidence of oncology diseases like prostate cancer, lung cancer, and breast cancer is on the rise, leading to a growing need for prompt and effective management to mitigate mortality rates. This significant trend is driving the expansion of the single dose radiotherapy market. For example, Breastcancer.org reported that in March 2022, approximately 287,850 new cases of invasive breast cancer and 51,400 new cases of non-invasive (in situ) breast cancer are projected to be diagnosed among women in the United States.

Report Attribute Details
Expected Market Value (2023) US$ 7.88 billion
Anticipated Forecast Value (2033) US$ 16 billion
Projected Growth Rate (2023 to 2033) CAGR 7.3%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2017 to 2022 Single Dose Radiotherapy Services Demand Analysis vs. Forecast 2023 to 2033

The single dose radiotherapy services market was worth US$ 4.6 billion in 2017. It accumulated a market value of US$ 6.1 billion in 2022 while growing at a CAGR of 5.8% during the historical period.

Breast cancer, a progressive illness, affects over 2 million individuals globally and has a substantial impact on female mortality rates. Likewise, prostate cancer diagnoses exceed 1.4 million in men aged 45 years and above worldwide. The increasing occurrence of breast and prostate cancer has driven the expansion of the single-dose radiotherapy services market.

In the past, the limited availability of clinical data on single-dose radiotherapy hindered its widespread use in treating early-stage breast and prostate cancer. However, the current landscape is witnessing numerous ongoing clinical trials aimed at demonstrating the effectiveness and safety of single-dose radiotherapy in early-stage cancer treatment. These trials are paving the way for broader adoption by radiologists, as it holds the potential to reduce the time and costs associated with multiple fraction radiotherapy.

An example of pioneering work in the field is being conducted by the oncologists at the TARGIT Collaborative Group (TCG), who are actively engaged in the advancement of a groundbreaking form of single-dose radiotherapy called TARGIT-IORT. According to their research, TARGIT-IORT involves the precise administration of targeted radiation directly to the breast during surgery, shortly after tumor removal. Remarkably, 8 out of 10 patients who received TARGIT-IORT immediately following lumpectomy did not require any further radiotherapy treatments after this combined procedure. The market is projected to be worth US$ 16 billion by the end of forecast period while exhibiting a CAGR of 7.3%.

Comparative View of Single Dose Radiotherapy Services Market

Single Dose Radiotherapy Services Market:

Attributes Single Dose Radiotherapy Services Market
CAGR (2023 to 2033) 7.3%
Market Value (2033) US$ 16 billion
Growth Factor Increasing prevalence of breast and prostate cancan are expected to drive market growth.
Opportunity Increasing number of clinical trials for developing a more effective treatment solution is expected to create numerous opportunities for market expansion.

Radiotherapy Devices Market:

Attributes Radiotherapy Devices Market
CAGR (2023 to 2033) 10.4%
Market Value (2033) US$ 17.2 billion
Growth Factor The market is expected to be driven by the rising prevalence of cancer caused due to working with toxic chemicals, consuming a high-fat diet, and smoking habits.
Opportunity The launch of several software solutions and new technologically advanced products are expected to create various prospects for the industry expansion.

Radiotherapy Patient Positioning Accessories Market:

Attributes Radiotherapy Patient Positioning Accessories Market
CAGR (2023 to 2033) 4.8%
Market Value (2033) US$ 993.6 million
Growth Factor The market is anticipated to witness significant growth during the forecast period owing to the rising prevalence of cancer and advancements in technology.
Opportunity The launch of new products such as 3D printed positioning accessories and robotic patient positioning systems are expected to offer new opportunities for market growth.
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Which are Some Prominent Drivers Spearheading the Single Dose Radiotherapy Services Market?

Adoption of External Beam Radiation Therapy to fuel Market Growth

The demand for radiotherapy has significantly risen in recent years due to various factors. These include a growing number of cancer patients, a rise in the geriatric population, greater adoption of radiotherapy devices and procedures, an increase in awareness campaigns promoting the benefits of radiotherapy, and advances in radiotherapy technology.

The adoption of external-beam radiation therapy has surged significantly, driven by its effectiveness in treating a broad range of cancers, including lung, prostate, breast, colorectal, liver, thyroid, lymphoma, brain, and spine cancer. This type of radiation therapy is highly favored and widely used in cancer treatment. It involves directing high-energy rays toward the tumor from outside the body, which has propelled its popularity and contributed to market growth.

The presence of reimbursement policies is expected to create numerous market opportunities for industry expansion. Various reimbursement policies associated with brachytherapy products have led to reduced treatment costs, incentivizing patients to seek treatment. For example, Isoray's announcement of approved billing codes for Cesium-131 reimbursement in hospital DRG sets in 2020 has accelerated market growth significantly. This factor plays a crucial role in driving rapid market expansion.

What are the Challenges Projected to be faced by the Market?

Lack of Skilled Professionals to Restrain Market Expansion

The lack of skilled professionals and a lack of technical expertise is expected to restrain market growth. The shortage of oncologists in the United States is a significant concern, with American Society of Clinical Oncology (ASCO) projecting a deficit of over 2,200 oncologists by 2025. Consequently, these factors act as obstacles to the expansion of the market.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Region-Wise Insights

What is the Growth Outlook in North America?

North America Driving Growth with Significant CAGR

The North American single dose radiotherapy services market accounted for a revenue share of 41% in 2022. The demand outlook for single dose radiotherapy services treatment in the region is expected to grow with a CAGR of 7.1% during the forecast period.

The United States healthcare system is renowned for its advanced infrastructure and high expenditures. Cancer care centers and hospitals adhere to regulatory guidelines and insurance policies in their treatment protocols. The substantial hospital bills, apart from those covered by Medicare, contribute to the growth of the market in the country.

The United States government and regulatory authorities are actively implementing cost-containment plans to alleviate the healthcare burden. In addition, they are taking proactive initiatives to promote research activities focused on the development and treatment plans for single-dose radiotherapy in cancer care.

As an example, in 2019, the American Cancer Society provided over $67 million in funding for breast cancer research via 162 research and training grants. Moreover, the American Cancer Society Cancer Action Network (ACS CAN) augmented the funding for the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) at both state and federal levels.

The United States witnesses a higher prevalence of breast cancer and prostate cancer, prompting numerous service providers to initiate awareness campaigns to educate the public about these diseases. This increased awareness is expected to positively impact the overall market growth in the country.

How Big Is the Opportunity in East Asia?

China to emerge as an important Player in the Single Dose Radiotherapy Services Domain

The market in East Asia is expected to grow with a CAGR of 7.4% throughout the forecast period. The market in China is projected to grow at a CAGR of 7.5% during the forecast period.

South Asia is poised for accelerated growth in the coming years. According to the World Health Organization, there has been an upward trend in the incidence rate of "westernized lifestyle-related cancer," including prostate cancer in males, as well as obesity and hormonal exposure-related cancers such as breast cancer in females, reported in China in 2018.

In China, a comprehensive nationwide survey conducted in 2018 indicated that approximately 13.8% of females were affected by breast cancer, while 19.25% of males were diagnosed with prostate cancer. Additionally, according to the Global Burden of Disease Study, both breast cancer and prostate cancer emerged as the leading causes of death among the top five types of cancer in the country in 2018.

These statistics reflect significant opportunities for expanded penetration in China, thereby extending to South Asia. The increasing incidence of breast cancer and prostate cancer in China serves as a crucial driver for rapid growth of the market in the region.

A rise in government spending on healthcare, increasing funding for cancer research, and growing prevalence of cancer is expected to propel market growth in the region. Additionally, government initiatives toward strengthening healthcare facilities and increasing health insurance penetration are further fuelling the demand for single dose radiotherapy services.

Category wise Insights

By Therapy, Which Segment is most likely to experience Maximum Uptake?

External Beam Radiotherapy Leading the Market

The external beam radiotherapy segment is expected to lead the single dose radiotherapy services market. This segment is expected to flourish at a CAGR of 7.9% throughout the forecast period.

The growth of the market is primarily attributed to the remarkable precision achieved through external beam therapy. Advancements in this therapy enable the delivery of higher and more precise radiation doses while minimizing harm to healthy tissues. Additionally, patients who are deemed unfit for surgery, further driving its popularity in the market, prefer external radiotherapy.

External beam radiotherapy is a commonly utilized treatment approach for breast cancer and prostate cancer. Its ease of operation and non-invasive nature make it a preferred choice among physicians. While external beam radiotherapy can be costly, many service providers offer reimbursement options for these procedures. Interestingly, the cost of a single dose of external beam radiotherapy is typically higher for prostate cancer patients compared to breast cancer patients, resulting in higher revenue within the single-dose radiotherapy services market.

By Indication, Which Segment is Expected to Hold a Sizeable Share?

Prostate Cancer Indication to account for maximum deployment

The prostate cancer segment is expected to account for a sizeable share by end of the forecast period. The segment is expected to grow with a CAGR of 8% during the forecast period.

The growth of this segment can be attributed to the significant incidence of prostate cancer and its relatively high success rate compared to other types of cancer. For example, data from GLOBOCAN indicates that there were 1.4 million reported cases of prostate cancer in 2020, with an expected increase to 1.9 million cases by 2040. This sustained rise in cases contributes to the segment growth as well as the overall growth of the market.

Start-ups in Single Dose Radiotherapy Services Market

Start-ups are crucial in identifying growth opportunities, including the single-dose radiotherapy services market. They efficiently convert inputs to outputs and adapt to market changes, contributing to the industry's expansion. Some start-ups are expected to drive growth in the single-dose radiotherapy services market.

  • RifleXion is a company that provides a biology-guided radiotherapy system. Their patented technology makes use of Positron Emission Tomography (PET) to enable tumors to continually indicate their location during treatment, thereby guiding personalized radiation therapy. This technology is useful in treating lung, prostate, and breast cancers.
  • Alpha Tau Medical is a company specializing in the development of a radiotherapy technique for the treatment of solid cancer tumors. Their innovative technology, called Alpha DaRT, involves the use of interstitial radioactive seeds that continuously release short-lived alpha-emitting atoms into the tumor.
  • Avenda Health is a company focused on developing a focal therapy system designed specifically for the treatment of prostate cancer.

Market Competition

The single dose radiotherapy services market is highly competitive, with several key industry players investing heavily in the production of these services. The key industry players are Accuray Incorporated, Varian Medical Systems, Inc., Elekta AB, ViewRay, Inc., IBA Worldwide, Alliance Oncology, GenesisCare, Hitachi, Ltd., RaySearch Laboratories AB, and Provision Healthcare.

Key industry players leverage organic growth strategies like acquisition, mergers, partnerships, and collaboration to enhance their product portfolio. This is expected to fuel the global single dose radiotherapy services market.

  • In June 2021, Elekta and Philips entered into a strategic partnership agreement with the aim of advancing personalized cancer care through precision solutions.
  • Accuray Incorporated launched the CyberKnife S7 System in June 2020, offering advanced precision and real-time radiation delivery capabilities.
  • RifleXion Medical demonstrated the efficacy of biology-guided radiation (BgRT) for all cancer stages in June 2022

Report Scope

Report Attribute Details
Market Value in 2023 US$ 7.88 billion
Market Value in 2033 US$ 16 billion
Growth Rate CAGR of 7.3% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2017 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Indication
  • Therapy
  • Service Providers
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa
Key Countries Profiled
  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • China
  • Japan
  • Malaysia
  • Singapore
  • Thailand
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Accuray Incorporated
  • Varian Medical Systems, Inc.
  • Elekta AB
  • ViewRay Inc.
  • IBA Worldwide
  • Alliance Oncology
  • GenesisCare
  • Hitachi, Ltd.
  • RaySearch Laboratories AB
  • Provision Healthcare
Customization & Pricing Available Upon Request

Key Segments Profiled in the Single Dose Radiotherapy Services Industry Survey

Indication:

  • Breast Cancer
  • Prostate Cancer

Therapy:

  • External Beam Radiotherapy
  • Internal Beam Radiotherapy

Service Provider:

  • Hospitals
  • Radiotherapy Centers
  • Specialized Cancer Institutes

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Middle East and Africa
  • Oceania

Frequently Asked Questions

What is the Current Market Valuation?

The market is estimated to secure a valuation of US$ 7.88 billion in 2023.

How Big will be the Single Dose Radiotherapy Services Market by 2033?

The market is estimated to US$ 16 billion by 2033.

What is the Growth Potential of the Market?

Through 2033, the market is anticipated to expand at a 7.3% CAGR.

What is the Current Market Valuation in China?

The market in China is set to progress at a CAGR of 7.5%.

What is the Market Outlook of the North America?

The North American market makes up 41% of total revenue.

Which Therapy Segment Can Boost at a Vital Market CAGR?

External beam radiotherapy segment is experiencing significant growth in the industry, with a CAGR of 6.9%.

Which Indication Segment Is Set to Secure Market Momentum?

The prostate cancer segment is to thrive at a CAGR of 8%.

Table of Content
1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2017 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033

        5.3.1. Breast Cancer

        5.3.2. Prostate Cancer

    5.4. Y-o-Y Growth Trend Analysis By Indication, 2017 to 2022

    5.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033

6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Therapy

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Therapy, 2017 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy, 2023 to 2033

        6.3.1. External Beam Radiotherapy

        6.3.2. Internal Beam Radiotherapy

    6.4. Y-o-Y Growth Trend Analysis By Therapy, 2017 to 2022

    6.5. Absolute $ Opportunity Analysis By Therapy, 2023 to 2033

7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Service Provider 

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Service Provider, 2017 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Service Provider, 2023 to 2033

        7.3.1. Hospitals

        7.3.2. Radiotherapy Centers

        7.3.3. Specialized Cancer Institutes

    7.4. Y-o-Y Growth Trend Analysis By Service Provider, 2017 to 2022

    7.5. Absolute $ Opportunity Analysis By Service Provider, 2023 to 2033

8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia

        8.3.5. East Asia

        8.3.6. Oceania

        8.3.7. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Indication

        9.2.3. By Therapy

        9.2.4. By Service Provider

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Indication

        9.3.3. By Therapy

        9.3.4. By Service Provider

    9.4. Key Takeaways

10. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Indication

        10.2.3. By Therapy

        10.2.4. By Service Provider

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Indication

        10.3.3. By Therapy

        10.3.4. By Service Provider

    10.4. Key Takeaways

11. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. UK

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Indication

        11.2.3. By Therapy

        11.2.4. By Service Provider

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Indication

        11.3.3. By Therapy

        11.3.4. By Service Provider

    11.4. Key Takeaways

12. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Rest of South Asia

        12.2.2. By Indication

        12.2.3. By Therapy

        12.2.4. By Service Provider

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Indication

        12.3.3. By Therapy

        12.3.4. By Service Provider

    12.4. Key Takeaways

13. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Indication

        13.2.3. By Therapy

        13.2.4. By Service Provider

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Indication

        13.3.3. By Therapy

        13.3.4. By Service Provider

    13.4. Key Takeaways

14. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Indication

        14.2.3. By Therapy

        14.2.4. By Service Provider

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Indication

        14.3.3. By Therapy

        14.3.4. By Service Provider

    14.4. Key Takeaways

15. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Indication

        15.2.3. By Therapy

        15.2.4. By Service Provider

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Indication

        15.3.3. By Therapy

        15.3.4. By Service Provider

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Indication

            16.1.2.2. By Therapy

            16.1.2.3. By Service Provider

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Indication

            16.2.2.2. By Therapy

            16.2.2.3. By Service Provider

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Indication

            16.3.2.2. By Therapy

            16.3.2.3. By Service Provider

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Indication

            16.4.2.2. By Therapy

            16.4.2.3. By Service Provider

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Indication

            16.5.2.2. By Therapy

            16.5.2.3. By Service Provider

    16.6. UK

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Indication

            16.6.2.2. By Therapy

            16.6.2.3. By Service Provider

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Indication

            16.7.2.2. By Therapy

            16.7.2.3. By Service Provider

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Indication

            16.8.2.2. By Therapy

            16.8.2.3. By Service Provider

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Indication

            16.9.2.2. By Therapy

            16.9.2.3. By Service Provider

    16.10. India

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Indication

            16.10.2.2. By Therapy

            16.10.2.3. By Service Provider

    16.11. Malaysia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Indication

            16.11.2.2. By Therapy

            16.11.2.3. By Service Provider

    16.12. Singapore

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Indication

            16.12.2.2. By Therapy

            16.12.2.3. By Service Provider

    16.13. Thailand

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Indication

            16.13.2.2. By Therapy

            16.13.2.3. By Service Provider

    16.14. China

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Indication

            16.14.2.2. By Therapy

            16.14.2.3. By Service Provider

    16.15. Japan

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Indication

            16.15.2.2. By Therapy

            16.15.2.3. By Service Provider

    16.16. South Korea

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Indication

            16.16.2.2. By Therapy

            16.16.2.3. By Service Provider

    16.17. Australia

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Indication

            16.17.2.2. By Therapy

            16.17.2.3. By Service Provider

    16.18. New Zealand

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Indication

            16.18.2.2. By Therapy

            16.18.2.3. By Service Provider

    16.19. GCC Countries

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Indication

            16.19.2.2. By Therapy

            16.19.2.3. By Service Provider

    16.20. South Africa

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Indication

            16.20.2.2. By Therapy

            16.20.2.3. By Service Provider

    16.21. Israel

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Indication

            16.21.2.2. By Therapy

            16.21.2.3. By Service Provider

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Indication

        17.3.3. By Therapy

        17.3.4. By Service Provider

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Accuray Incorporated

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Varian Medical Systems, Inc.

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Elekta AB

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. ViewRay, Inc.

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. IBA Worldwide

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Alliance Oncology

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. GenesisCare

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Hitachi, Ltd.

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. RaySearch Laboratories AB

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Provision Healthcare

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology
Recommendations

Healthcare

Radiotherapy Induced Oral Mucositis Treatment Market

March 2023

REP-GB-16820

February 2024

342 pages

Healthcare

Radiotherapy Device Market

August 2017

REP-GB-1556

October 2023

325 pages

Healthcare

Radiotherapy Patient Positioning Accessories Market

February 2022

REP-GB-9325

March 2023

345 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Single Dose Radiotherapy Services Market